Statement of Delegation of Authority, 2708-2709 [2025-00432]

Download as PDF 2708 Federal Register / Vol. 90, No. 7 / Monday, January 13, 2025 / Notices ANNUAL BURDEN ESTIMATES Instrument Number of respondents Number of responses per respondent ANA Project Outcome Assessment Survey .................................................................. 85 1 Authority: 42 U.S.C. 2992. Mary C. Jones, ACF/OPRE Certifying Officer. [FR Doc. 2025–00490 Filed 1–10–25; 8:45 am] BILLING CODE 4184– 34–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Center for Scientific Review; Notice of Closed Meetings ddrumheller on DSK120RN23PROD with NOTICES1 Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Oncology 1-Basic Translational Integrated Review Group; Cancer Cell Biology Study Section Date: February 6–7, 2025. Time: 10:00 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892. Meeting Format: Virtual Meeting. Contact Person: Alyssa Diane Gregory, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, alyssa.gregory@nih.gov. Name of Committee: Biobehavioral and Behavioral Processes Integrated Review Group; Child Psychopathology and Developmental Disabilities Study Section. Date: February 10–12, 2025. Time: 9:00 a.m. to 7:00 p.m. Agenda: To review and evaluate grant applications. Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892. Meeting Format: Virtual Meeting. Contact Person: Karen Elizabeth Seymour, Ph.D., Scientific Review Officer, Center for VerDate Sep<11>2014 18:48 Jan 09, 2025 Jkt 265001 Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 1000–E, Bethesda, MD 20892, (301) 443–9485, karen.seymour@nih.gov. Name of Committee: Genes, Genomes, and Genetics Integrated Review Group; Maximizing Investigators’ Research Award— F Study Section. Date: February 10–11, 2025. Time: 10:00 a.m. to 6:30 p.m. Agenda: To review and evaluate grant applications. Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892. Meeting Format: Virtual Meeting. Contact Person: Brian Paul Chadwick, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 594–3586, chadwickbp@ csr.nih.gov. Name of Committee: Brain Disorders and Clinical Neuroscience, Integrated Review Group; Brain Injury and Neurovascular Pathologies Study Section. Date: February 10–11, 2025. Time: 10:00 a.m. to 7:00 p.m. Agenda: To review and evaluate grant applications. Address: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892. Meeting Format: Virtual Meeting. Contact Person: Alexander Yakovlev, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5206, MSC 7846, Bethesda, MD 20892, 301–435– 1254, yakovleva@csr.nih.gov. Name of Committee: Interdisciplinary Molecular Sciences and Training Integrated Review Group; Cellular and Molecular Technologies Study Section. Date: February 11–12, 2025. Time: 9:00 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892. Meeting Format: Virtual Meeting. Contact Person: Tatiana V. Cohen, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5213, Bethesda, MD 20892, 301–455–2364, tatiana.cohen@nih.gov. Name of Committee: Biological Chemistry and Macromolecular Biophysics Integrated Review Group; Macromolecular Structure and Function B Study Section. Date: February 11–12, 2025. Time: 9:30 a.m. to 8:00 p.m. Agenda: To review and evaluate grant applications. PO 00000 Frm 00045 Fmt 4703 Sfmt 4703 Average burden hours per response I 6 Annual burden hours I 510 Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892. Meeting Format: Virtual Meeting. Contact Person: Alexei A. Yeliseev, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 443–0552, yeliseeva@ mail.nih.gov. Name of Committee: Infectious Diseases and Immunology A Integrated Review Group; Pathogenic Eukaryotes Study Section. Date: February 11–12, 2025. Time: 9:30 a.m. to 7:00 p.m. Agenda: To review and evaluate grant applications. Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892. Meeting Format: Virtual Meeting. Contact Person: Jennifer Chien Villa, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, 301–496–5436, jennifer.villa@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS) Dated: January 6, 2025. Lauren A. Fleck, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2025–00458 Filed 1–10–25; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Statement of Delegation of Authority Notice is hereby given that I have delegated to the Director, National Institutes of Health (NIH), the authority vested in the Secretary of Health and Human Services under the Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinson’s Act (Pub. L. 118–66) (Act). The Act amends Title III of the Public Health Service Act by adding section 399OO, 42 U.S.C. 280n. The Act directs the Secretary to carry out a national project to prevent, diagnose, treat, and cure Parkinson’s, to be known as the National Parkinson’s Project, including E:\FR\FM\13JAN1.SGM 13JAN1 Federal Register / Vol. 90, No. 7 / Monday, January 13, 2025 / Notices a requirement to establish and maintain an Advisory Council on Parkinson’s Research, Care, and Services and to create, maintain, and periodically update a national plan to prevent, diagnose, treat, and cure Parkinson’s, ameliorate symptoms, and slow or stop progression. This authority may be redelegated. Exercise of this authority shall be in accordance with established policies, procedures, guidelines, and regulations as prescribed by the Secretary. The Secretary retains the authority to submit reports to Congress, promulgate regulations, and appoint members to the Advisory Council on Parkinson’s Research, Care, and Services. This Advisory Council will be co-chaired by the National Institutes of Health and the Office of the Assistant Secretary for Health. This delegation is effective immediately. Dated: January 6, 2025. Xavier Becerra, Secretary. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting ddrumheller on DSK120RN23PROD with NOTICES1 Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; HHS–NIH–CDC–SBIR PHS 2025–1 Phase I: Software or Web Services to Assess Quality and Reproducibility of Data and Information about Therapeutics and Vaccines (Topic 147). Date: February 5, 2025. Time: 10:00 a.m. to 3:00 p.m. Agenda: To review and evaluate contract proposals. Place: National Institute of Allergy and Infectious Diseases, National Institutes of 18:48 Jan 09, 2025 Jkt 265001 Dated: January 6, 2025. Lauren A. Fleck, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2025–00462 Filed 1–10–25; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES [FR Doc. 2025–00457 Filed 1–10–25; 8:45 am] National Institute of Neurological Disorders and Stroke; Notice of Closed Meeting BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting BILLING CODE 4140–01–P (Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS) Dated: January 6, 2025. Lauren A. Fleck, Program Analyst, Office of Federal Advisory Committee Policy. National Institutes of Health [FR Doc. 2025–00432 Filed 1–7–25; 11:15 am] VerDate Sep<11>2014 Health, 5601 Fishers Lane, Rockville, MD 20892 (Video Assisted Meeting). Contact Person: Sandip Bhattacharyya, Ph.D., Scientific Review Officer, Scientific Review Program, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, MSC–9823, Rockville, MD 20892, sandip.bhattacharyya@ nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS) 2709 Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; HHS–NIH–CDC–SBIR PHS– 2025–1 Phase I and II: Development of Medical Interventions for Treating NonTuberculosis Mycobacterial (NTM) Infections (Topic 144). Date: February 3, 2025. Time: 1:00 p.m. to 3:00 p.m. Place: National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Rockville, MD 20892 (Video Assisted Meeting). Agenda: To review and evaluate contract proposals. Contact Person: Mario Cerritelli, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, MSC–9823, Rockville, MD 20892, 240–669–5199, cerritem@ mail.nih.gov. PO 00000 Frm 00046 Fmt 4703 Sfmt 9990 National Institutes of Health Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Neurological Disorders and Stroke Initial Review Group; Neurological Sciences and Disorders C Study Section. Date: February 3–4, 2025. Time: 9:00 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Address: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852. Meeting Format: Virtual Meeting. Contact Person: Ana Olariu, Ph.D., Scientific Review Officer, Scientific Review Branch, Division of Extramural Activities, NINDS/NIH/DHHS, NSC, 6001 Executive Boulevard, Rockville, MD 20852, 301–496– 9223, Ana.Olariu@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.853, Clinical Research Related to Neurological Disorders; 93.854, Biological Basis Research in the Neurosciences, National Institutes of Health, HHS) Dated: January 6, 2025. David W. Freeman, Supervisory Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2025–00470 Filed 1–10–25; 8:45 am] BILLING CODE 4140–01–P E:\FR\FM\13JAN1.SGM 13JAN1

Agencies

[Federal Register Volume 90, Number 7 (Monday, January 13, 2025)]
[Notices]
[Pages 2708-2709]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2025-00432]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Statement of Delegation of Authority

    Notice is hereby given that I have delegated to the Director, 
National Institutes of Health (NIH), the authority vested in the 
Secretary of Health and Human Services under the Dr. Emmanuel Bilirakis 
and Honorable Jennifer Wexton National Plan to End Parkinson's Act 
(Pub. L. 118-66) (Act). The Act amends Title III of the Public Health 
Service Act by adding section 399OO, 42 U.S.C. 280n. The Act directs 
the Secretary to carry out a national project to prevent, diagnose, 
treat, and cure Parkinson's, to be known as the National Parkinson's 
Project, including

[[Page 2709]]

a requirement to establish and maintain an Advisory Council on 
Parkinson's Research, Care, and Services and to create, maintain, and 
periodically update a national plan to prevent, diagnose, treat, and 
cure Parkinson's, ameliorate symptoms, and slow or stop progression.
    This authority may be redelegated. Exercise of this authority shall 
be in accordance with established policies, procedures, guidelines, and 
regulations as prescribed by the Secretary. The Secretary retains the 
authority to submit reports to Congress, promulgate regulations, and 
appoint members to the Advisory Council on Parkinson's Research, Care, 
and Services. This Advisory Council will be co-chaired by the National 
Institutes of Health and the Office of the Assistant Secretary for 
Health. This delegation is effective immediately.

    Dated: January 6, 2025.
Xavier Becerra,
Secretary.
[FR Doc. 2025-00432 Filed 1-7-25; 11:15 am]
BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.